J.W. Park

632 total citations · 1 hit paper
10 papers, 433 citations indexed

About

J.W. Park is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, J.W. Park has authored 10 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Surgery. Recurrent topics in J.W. Park's work include Gastric Cancer Management and Outcomes (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Cerebrovascular and Carotid Artery Diseases (4 papers). J.W. Park is often cited by papers focused on Gastric Cancer Management and Outcomes (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Cerebrovascular and Carotid Artery Diseases (4 papers). J.W. Park collaborates with scholars based in United States, Germany and Japan. J.W. Park's co-authors include Ahsan M. Arozullah, Florian Lordick, Martin Schüler, Karl Dhaene, Daniel Maurus, Ö. Türeci, Kai Wiechen, Christoph Huber, Uğur Şahin and I. Bazin and has published in prestigious journals such as Annals of Oncology and ESMO Open.

In The Last Decade

J.W. Park

9 papers receiving 428 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021 244 citations Uğur Şahin, Ö. Türeci et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.W. Park United States	5	258	207	151	131	72	10	433
Ö. Türeci Germany	4	260 1.0×	211 1.0×	156 1.0×	135 1.0×	70 1.0×	5	440
Özlem Türeci Germany	5	120 0.5×	117 0.6×	130 0.9×	58 0.4×	21 0.3×	7	269
Andrew Krivoshik United States	7	225 0.9×	162 0.8×	64 0.4×	50 0.4×	21 0.3×	11	321
Benjamin L. Green United States	12	108 0.4×	161 0.8×	24 0.2×	93 0.7×	89 1.2×	26	499
Megan H. Crawley United States	8	127 0.5×	139 0.7×	24 0.2×	52 0.4×	154 2.1×	10	389
Michihiko Kogure Japan	9	78 0.3×	126 0.6×	42 0.3×	97 0.7×	14 0.2×	20	320
Zsolt Baranyai Hungary	9	43 0.2×	176 0.9×	49 0.3×	56 0.4×	11 0.2×	28	288
Junya Ueda Japan	3	50 0.2×	63 0.3×	201 1.3×	49 0.4×	6 0.1×	3	282

Countries citing papers authored by J.W. Park

Since Specialization

Citations

This map shows the geographic impact of J.W. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.W. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.W. Park more than expected).

Fields of papers citing papers by J.W. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.W. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.W. Park. The network helps show where J.W. Park may publish in the future.

Co-authorship network of co-authors of J.W. Park

This figure shows the co-authorship network connecting the top 25 collaborators of J.W. Park. A scholar is included among the top collaborators of J.W. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.W. Park. J.W. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Lordick, Florian, Eric Van Cutsem, Rui‐Hua Xu, et al.. (2024). Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 9(8). 103663–103663. 9 indexed citations

Lordick, Florian, Manish A. Shah, Kohei Shitara, et al.. (2023). 134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1524–S1524. 2 indexed citations

Ajani, Jaffer A., Florian Lordick, Y-J. Bang, et al.. (2023). LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1322–S1322.

Lordick, Florian, Eric Van Cutsem, Kohei Shitara, et al.. (2023). 1530P Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW. Annals of Oncology. 34. S860–S861. 1 indexed citations

Lordick, Florian, Manish A. Shah, Kohei Shitara, et al.. (2023). LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1321–S1321. 1 indexed citations

Ajani, Jaffer A., Florian Lordick, Peter C. Enzinger, et al.. (2023). 135MO Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1524–S1525. 1 indexed citations

Şahin, Uğur, Ö. Türeci, Georgy M. Manikhas, et al.. (2021). FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Annals of Oncology. 32(5). 609–619. 244 indexed citations breakdown →

Shitara, Kohei, S-E. Al-Batran, Y-J. Bang, et al.. (2020). 198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ). Annals of Oncology. 31. S1317–S1317. 9 indexed citations

Ajani, Jaffer A., S-E. Al-Batran, Y-J. Bang, et al.. (2020). 195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ). Annals of Oncology. 31. S1315–S1316. 5 indexed citations

10.

Türeci, Ö., Uğur Şahin, Henning Schulze‐Bergkamen, et al.. (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology. 30(9). 1487–1495. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact